Atossa Genetics

Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. It offers ForeCYTE and ArgusCYTE diagnostic tests. The ForeCYTE Breast Health Test provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 65. The ArgusCYTE Breast Health Test offers information to help inform about breast cancer treatment options and to help monitor potential recurrence. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.

Atossa Therapeutics is popular with the Reddit crowd. However, ATOS stock doesn't make the top 25 on the platform.

Atossa Therapeutics Has a Steep Climb Ahead of It

So, overvalued, with low squeeze odds, what's the best move with ATOS stock? Sell or avoid, before dilution and other factors push it back down to its pre-hype price levels of around $1 per share.

As its Meme Status Has Come and Gone, Skip Out on Atossa Therapeutics Stock

Atossa Therapeutics has made a pivot to assist in the battle to fight Covid-19. But it seems that investors in ATOS stock are finding this to be a message they've already heard.

Atossa Therapeutics May Look Tempting, but There's No Reason to Get in Now

Evofem Biosciences Inc

ReShape Lifesciences

Biotech penny stocks continue to make headway, here's 3 with high volume right now The post 3 Biotech Penny Stocks With High Volume To Watch in August appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Biotech Penny Stocks With High Volume To Watch in August

Cinedigm

Ever-Glory International Group

Senseonics Holdings

Penny stocks are as speculative as investments get, but if you don't mind the risk involved, these seven offer reasons to be interested. The post 7 Reddit Penny Stocks That Are Lighting Up the Internet and the Market appeared first on InvestorPlace.

7 Reddit Penny Stocks That Are Lighting Up the Internet and the Market

ATOS stock surged briefly in 2021 based on several catalysts, but none of them right now is supportive of its current price and valuation. The post With Zero Revenue, I Can't Get Excited About Atossa appeared first on InvestorPlace.

With Zero Revenue, I Can't Get Excited About Atossa

SEATTLE, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announces financial results for the fiscal quarter ended June 30, 2021, and provides an update on recent company developments.

Atossa Therapeutics Announces Second Quarter 2021 Financial Results - Provides Corporate Update and Information about Upcoming Stockholder Meeting

1847 GOEDEKER INC.

Globalstar

Mind Medicine MindMed

Cenntro Electric Group

SNDL Inc.

Uranium Energy

XpresSpa Group

These ten low-priced penny stocks have ample room to gain, making them each worthy of a small, speculative investment. The post 10 Penny Stocks to Buy to Create a $500 Portfolio appeared first on InvestorPlace.

10 Penny Stocks to Buy to Create a $500 Portfolio

Infinity Pharma

With biotech penny stocks heating up, here are 3 you need to know about in August The post Best Biotech Penny Stocks For Your Monday Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Biotech Penny Stocks For Your Monday Watchlist

SEATTLE, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current focus on breast cancer and COVID-19, today announces that Steven Quay, M.D., Ph.D., Atossa's President and CEO, and Kyle Guse, Atossa's Chief Financial Officer, will participate at the BTIG Virtual Biotechnology Conference on August 9-10, 2021.

Atossa Therapeutics to Present at the BTIG Virtual Biotechnology Conference on August 9-10, 2021

Investors have become wary of the risks surrounding Atossa's pipeline. That caution will continue pulling down ATOS stock The post The Bear Case for Atossa Therapeutics Makes More Sense at This Time appeared first on InvestorPlace.

The Bear Case for Atossa Therapeutics Makes More Sense at This Time

Given the early stages of Atossa's clinical trials, ATOS stock is too risky to get involved with at this point. The post Investors Should Avoid High-Risk Atossa Therapeutics appeared first on InvestorPlace.

Investors Should Avoid High-Risk Atossa Therapeutics

ATOS stock is on its way down today. As the biotech company announces a special shareholder meeting, holders worry about stock dilution.

ATOS Stock: The Big News That Has Atossa Therapeutics Plunging 20% Today

The potential with its breast cancer and Covid-19 treatment candidates notwithstanding, don't fight the trend with ATOS stock. The post Wait for Atossa Therapeutics Stock to Slide Further Before Buying appeared first on InvestorPlace.

Wait for Atossa Therapeutics Stock to Slide Further Before Buying

ATOS stock is a relatively unknown pharmaceutical firm that is worth keeping an eye on due to surging Covid-19 cases. The post Atossa Therapeutics Might Shoot Up Quickly on Covid-19 Fear appeared first on InvestorPlace.

Atossa Therapeutics Might Shoot Up Quickly on Covid-19 Fear

ATOS stock attracted social media for its possible short-squeeze play and its therapeutic offerings but speculators should be careful. The post Think Carefully Before Speculating on Atossa Therapeutics appeared first on InvestorPlace.

Think Carefully Before Speculating on Atossa Therapeutics

SEATTLE, July 26, 2021 /PRNewswire/ -- Physician-Scientist Steven Quay and a group of international scientists have published a pre-print, available here, entitled, "CONTAMINATION OR VACCINE RESEARCH? RNA Sequencing data of early COVID-19 patient samples show abnormal presence of vectorized H7N9 hemagglutinin segment.

Physician-Scientist Steven Quay: Forensic examination of Wuhan Institute of Virology COVID-19 patient specimens from December 2019 reveals extensive laboratory contamination, including evidence of genetic manipulation of the Nipah Virus, a BSL-4 pathogen 

Vinco Ventures

Reddit penny stocks are heating up right now; here's 3 to watch The post 3 Penny Stocks That Are Popular on Reddit Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Penny Stocks That Are Popular on Reddit Right Now

After a steep selloff, shares of Atossa Therapeutics, Inc. (NASDAQ: ATOS) have reached the critical $4 level. This level was support in early June.

Is Atossa Therapeutics Stock Breaking Important Support?

Traders will continue to analyze the short-squeeze potential of ATOS stock, but investors should also focus on Atossa's clinical progress. The post A Promising Covid-19 Treatment Makes Atossa Therapeutics Intriguing appeared first on InvestorPlace.

A Promising Covid-19 Treatment Makes Atossa Therapeutics Intriguing

SEATTLE, July 15, 2021 /PRNewswire/ -- An international team of scientists and data analysts, led by Physician-Scientist Steven Quay, MD, PhD, has published a paper entitled, "Science Not Speculation Should Inform the Investigation of the Origin of COVID-19," in which they conclude: "Until new evidence is found, an investigation of the pathway for the origin of COVID-19 should proceed with the assumption that a laboratory-acquired infection or research-related accident is at least as likely, if not more likely, than a natural zoonotic transmission." The paper was submitted to the Subcommittee on Investigations and Oversight hearing, Principles for Outbreak Investigation: COVID-19 and Future Infectious Diseases," held on July 14, 2021.

Physician-Scientist Steven Quay and an International Team of Scientists and Investigators Provide Science-Based Analysis of the Origin of COVID-19 to the US Congress

Atossa Therapeutics Inc (NASDAQ: ATOS) shares are trading higher Tuesday after retail traders were able to push the stock higher. The stock was trading on above-average volume Tuesday and was trending on social media sites throughout the day such as StockTwits.

Atossa Therapeutics Stock Runs While Trading In Bearish Pattern

Nebulized formulation being developed to improve lung function in both active-disease COVID-19 patients and “Long Haul” patients with post-infection pulmonary disease

Atossa Therapeutics Receives Regulatory Approval To Open Clinical Study of AT-H201 in Australia

The Reddit crowd might decide to target ATOS stock for a short squeeze, but that's not the only reason to take a long position today. The post The Bulls Are in Charge of Atossa Therapeutics appeared first on InvestorPlace.

The Bulls Are in Charge of Atossa Therapeutics

Investors want to know if this clinical-stage cancer drug developer can keep putting up big gains.

News for Atossa Genetics Stock (ATOS)